- Home
- ACAD vs CATY Comparison
ACAD vs CATY Comparison
Compare ACAD & CATY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- CATY
- Stock Information
- Founded
- ACAD 1993
- CATY 1962
- Country
- ACAD United States
- CATY United States
- Employees
- ACAD N/A
- CATY N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- CATY Major Banks
- Sector
- ACAD Health Care
- CATY Finance
- Exchange
- ACAD Nasdaq
- CATY Nasdaq
- Market Cap
- ACAD 2.5B
- CATY 2.7B
- IPO Year
- ACAD 2004
- CATY N/A
- Fundamental
- Price
- ACAD $17.44
- CATY $42.94
- Analyst Decision
- ACAD Buy
- CATY Hold
- Analyst Count
- ACAD 15
- CATY 5
- Target Price
- ACAD $24.21
- CATY $49.60
- AVG Volume (30 Days)
- ACAD 1.8M
- CATY 427.4K
- Earning Date
- ACAD 05-07-2025
- CATY 04-21-2025
- Dividend Yield
- ACAD N/A
- CATY 3.17%
- EPS Growth
- ACAD N/A
- CATY N/A
- EPS
- ACAD 1.37
- CATY 3.95
- Revenue
- ACAD $996,283,000.00
- CATY $691,279,000.00
- Revenue This Year
- ACAD $13.07
- CATY $16.75
- Revenue Next Year
- ACAD $10.06
- CATY $7.13
- P/E Ratio
- ACAD $12.74
- CATY $10.87
- Revenue Growth
- ACAD 22.42
- CATY N/A
- 52 Week Low
- ACAD $13.40
- CATY $34.46
- 52 Week High
- ACAD $20.68
- CATY $55.29
- Technical
- Relative Strength Index (RSI)
- ACAD 67.70
- CATY 56.48
- Support Level
- ACAD $14.45
- CATY $40.96
- Resistance Level
- ACAD $15.31
- CATY $43.67
- Average True Range (ATR)
- ACAD 0.69
- CATY 1.40
- MACD
- ACAD 0.37
- CATY 0.31
- Stochastic Oscillator
- ACAD 94.92
- CATY 83.10
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About CATY Cathay General Bancorp
Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities and advisory services.